EGFR and non-small cell lung carcinoma: However, cabozantinib plus atezolizumab only demonstrated modest activity in 30 patients with previously‐treated advanced EGFR‐mutated NSCLC (ORR = 7%, DCR = 63%, median PFS = 2.7 months, and median OS = 6.1 months).35